Fundraising Fox
Annexon
So. San Francisco, US · Founded 2011 · 114 employees on LinkedIn · 15 known investors
Find your way into Annexon
Each arrow is one introduction. Sign up to fill in the first one.
Ask LaToya Coffey to introduce you to Douglas Love
You →LaToya · together at Annexon →Douglas
Sign up to find every way you can get introduced to Annexon
- Your email: who you already know at Annexon, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Annexon team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
Founders & leadership
Annexon was founded in 2011 by Ben Barres and Douglas Love.
Board
Investors · 15
How we know: Bain Capital Life Sciences's portfolio page · biospace.com · Not right? Tell us
How we know: Correlation Ventures's portfolio page · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
How we know: funding news · biospace.com · Not right? Tell us
Also in the syndicate · 6
Reported raises · per SEC filings
Form D private placements$277.5M disclosed across 3 of 5 rounds · 2018–2025
▶$130.5MraisedJul 2022 · 12 investors · BiotechnologyRule 506(b)
- William D. WaddillDirector
- Thomas G. WiggansDirector
- Muneer A. SatterDirector
- Michael OverdorfExecutive Officer
- Larry C. Mattheakis, Ph.DExecutive Officer
- Douglas LoveExecutive Officer, Director
- Jennifer LewExecutive Officer
- Bettina M. Cockroft, M.D.Director
- William H. Carson, M.D.Director
- Jung E. ChoiDirector
- Offering amount
- $130.5M
- Amount sold
- $130.5M
- Sales commissions
- $6.7M
- Placement agents
- Jefferies LLC, Cowen and Company, LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$102MraisedJul 2020 · 17 investors · BiotechnologyRule 506(b)
- Ted YednockExecutive Officer
- Jung E. ChoiDirector
- William D. YoungDirector
- Emmett CunninghamDirector
- Thomas G. WiggansDirector
- Carol GallagherDirector
- Muneer A. SatterDirector
- Campbell MurrayDirector
- Sanjay KeswaniExecutive Officer
- Jennifer LewExecutive Officer
- Douglas LoveExecutive Officer, Director
- Ricky SunDirector
- Offering amount
- $102M
- Amount sold
- $102M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedDec 2018 · 10 investors · BiotechnologyRule 506(b)
- Campbell MurrayDirector
- Douglas LoveExecutive Officer, Director
- Thomas WiggansDirector
- Emmett CunninghamDirector
- Ricky SunDirector
- Muneer SatterDirector
- Carol GallagherDirector
- Ted YednockExecutive Officer
- William YoungDirector
- Mark L SmithExecutive Officer
- Offering amount
- $85M
- Amount sold
- $45M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Annexon went on to found or lead other companies.
In the news
Frequently asked questions
- What does Annexon do?
- Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases. Its therapies aim to block complement-driven damage affecting the body, brain, and eye.
- Who founded Annexon?
- Annexon was founded by Ben Barres, Douglas Love in 2011.
- Who are Annexon's investors?
- Annexon's investors include Bain Capital Life Sciences, Correlation Ventures, New Enterprise Associates (NEA), BlackRock, Blackstone Life Sciences, Clarus Ventures, Deerfield Management Company, Janus Henderson Investors and 1 more.
- How much funding has Annexon raised?
- Annexon has disclosed $277.5M raised across 3 of its 5 known rounds.
- Where is Annexon headquartered?
- Annexon is headquartered in So. San Francisco, US.